Clinical Trial

Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is being done to determine if two different anti-cancer drugs, paclitaxel (PTX) and pegylated liposomal doxorubicin (PLD) have similar effects on treating Kaposi Sarcoma (KS) in people living with HIV (human immunodeficiency virus) in sub-Saharan Africa. Patients with HIV-related KS will receive either PTX or PLD once every 3 weeks for a total of six cycles.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2022-06-06; most recent amendment 2026-01-22.
Trial Details
NCT Number NCT05411237
Lead Sponsor AIDS Malignancy Consortium
Collaborators: National Cancer Institute (NCI)
Conditions Kaposi Sarcoma, HIV-1-infection, AIDS-related Kaposi Sarcoma
Enrollment 130 participants
Start Date 2026-09
Primary Completion 2029-09 (estimated)
Study Completion 2030-09 (estimated)
Updated on ClinicalTrials.gov 2026-01-23